|

IMVT-1402 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since May 2026

Pipeline

Phase 3: 1

Top Sponsors

  • Immunovant Sciences GmbH1

Indications

  • Generalized Myasthenia Gravis1
  • Cancer1

Huntsville, Alabama1 trial

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Site Number - 1056

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.